![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessValidation of the Greek Version of the Diabetes Management Self-Efficacy Scale (GR-DMSES)
Self-efficacy has been found to have a direct relation with self-care in diabetes. Several tools have been developed and used for evaluating self-efficacy of diabetic patients, the most widely used being the D...
-
Article
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective
Sodium-Glucose linked transporter 2 (SGLT2) inhibitors are a new family of antidiabetic pharmaceutical agents whose action is based on the inhibition of the glucose reabsorption pathway, resulting in glucosuri...
-
Article
Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology
Combination therapies are a widely accepted approach to type 2 diabetes treatment, considering that monotherapies fail to provide adequate glycemic control in the majority of cases. The combination of oral ant...
-
Article
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy
Diabetes mellitus (DM) is currently considered to be an epidemic disease. A safe and effective treatment has long been sought by scientists. Incretin mimetics and dipeptidyl peptidase-4 (DPP4) inhibitors repre...
-
Article
DPP4 Inhibitors: a new approach in diabetes treatment
The role of dipeptidyl peptidase-IV (DPP4) as both a regulatory enzyme and a signalling factor has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the ...